CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps
December 22, 2021
Medicare coverage for Medtronic customers will be available 60 days after official publication
DUBLIN, Dec. 22, 2021 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.
Medtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes
April 7, 2021
New Partnerships and Research Efforts Prioritized Over the Next Three Years to Address Health Disparities
April 7, 2021 - MINNEAPOLIS, /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange, as well as additional research efforts, to better understand and address these disparities.
Medtronic Commends CMS on Proposed Rule to Expand Medicare Coverage for All CGMs
October 28, 2020
October 28, 2020 – On October 27th, the Centers for Medicare & Medicaid Services (CMS) announced proposed new changes that, if finalized, would expand Medicare coverage for Continuous Glucose Monitors (CGMs) that provide critical information on glucose levels to help people with diabetes better manage their disease. We are very encouraged by CMS’s proposed rule and commend the agency on taking action to help more people with diabetes.
Medtronic Announces FDA Approval for MiniMed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes
September 1, 2020
DUBLIN – September 1, 2020 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system. This newest insulin pump system offers the company’s most advanced SmartGuard™ technology, as featured in the MiniMed™ 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.
Medtronic Plans To Acquire Smart Insulin Pen Company Companion Medical
August 11, 2020
DUBLIN and SAN DIEGO – August 11, 2020 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical’s InPen to the Medtronic portfolio expands the company’s ability to serve people where they are in their diabetes journey and offer them a unique and expansive ecosystem of support — regardless of how insulin is delivered.
For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:
Sr Director, Global Communications
For all other media inquiries please select the appropriate Global Public and Media Relations contact